<?xml version='1.0' encoding='utf-8'?>
<document id="28734977"><sentence text="Modulation of the interaction between human P450 3A4 and B. megaterium reductase via engineered loops." /><sentence text="Chimerogenesis involving cytochromes P450 is a successful approach to generate catalytically self-sufficient enzymes" /><sentence text=" However, the connection between the different functional modules should allow a certain degree of flexibility in order to obtain functional and catalytically efficient proteins" /><sentence text=" We previously applied the molecular Lego approach to develop a chimeric P450 3A4 enzyme linked to the reductase domain of P450 BM3 (BMR)" /><sentence text=" Three constructs were designed with the connecting loop containing no glycine, 3 glycine or 5 glycine residues and showed a different catalytic activity and coupling efficiency"><entity charOffset="71-78" id="DDI-PubMed.28734977.s5.e0" text="glycine" /></sentence><sentence text=" Here we investigate how the linker affects the ability of P450 3A4 to bind substrates and inhibitors" /><sentence text=" We measure the electron transfer rates and the catalytic properties of the enzyme also in the presence of ketoconazole as inhibitor"><entity charOffset="107-119" id="DDI-PubMed.28734977.s7.e0" text="ketoconazole" /></sentence><sentence text=" The data show that the construct 3A4-5GLY-BMR with the longest loop better retains the binding ability and cooperativity for testosterone, compared to P450 3A4"><entity charOffset="126-138" id="DDI-PubMed.28734977.s8.e0" text="testosterone" /></sentence><sentence text=" In both 3A4-3GLY-BMR and 3A4-5GLY-BMR, the substrate induces an increase in the first electron transfer rate and a shorter lag phase related to a domain rearrangements, when compared to the construct without Gly" /><sentence text=" These data are consistent with docking results and secondary structure predictions showing a propensity to form helical structures in the loop of the 3A4-BMR and 3A4-3GLY-BMR" /><sentence text=" All three chimeras retain the ability to bind the inhibitor ketoconazole and show an IC50 comparable with those reported for the wild type protein"><entity charOffset="61-73" id="DDI-PubMed.28734977.s11.e0" text="ketoconazole" /></sentence><sentence text=" This article is part of a Special Issue entitled: Cytochrome P450 biodiversity and biotechnology, edited by Erika Plettner, Gianfranco Gilardi, Luet Wong, Vlada Urlacher, Jared Goldstone"><entity charOffset="178-187" id="DDI-PubMed.28734977.s12.e0" text="Goldstone" /></sentence><sentence text="" /></document>